514 related articles for article (PubMed ID: 12407439)
1. The hypercoagulable state of malignancy: pathogenesis and current debate.
Caine GJ; Stonelake PS; Lip GY; Kehoe ST
Neoplasia; 2002; 4(6):465-73. PubMed ID: 12407439
[TBL] [Abstract][Full Text] [Related]
2. The prothrombotic state in cancer: pathogenic mechanisms.
De Cicco M
Crit Rev Oncol Hematol; 2004 Jun; 50(3):187-96. PubMed ID: 15182825
[TBL] [Abstract][Full Text] [Related]
3. Pathogenesis of thrombosis in patients with malignancy.
Falanga A; Donati MB
Int J Hematol; 2001 Feb; 73(2):137-44. PubMed ID: 11372723
[TBL] [Abstract][Full Text] [Related]
4. Pathophysiology of the thrombophilic state in the cancer patient.
Falanga A; Rickles FR
Semin Thromb Hemost; 1999; 25(2):173-82. PubMed ID: 10357085
[TBL] [Abstract][Full Text] [Related]
5. Thrombophilia in cancer.
Falanga A
Semin Thromb Hemost; 2005 Feb; 31(1):104-10. PubMed ID: 15706482
[TBL] [Abstract][Full Text] [Related]
6. Pathophysiology 1. Mechanisms of Thrombosis in Cancer Patients.
Falanga A; Schieppati F; Russo L
Cancer Treat Res; 2019; 179():11-36. PubMed ID: 31317478
[TBL] [Abstract][Full Text] [Related]
7. Cancer and thromboembolic disease: pathogenic mechanisms.
Lee AY
Cancer Treat Rev; 2002 Jun; 28(3):137-40. PubMed ID: 12234564
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of hypercoagulation in malignancy and during chemotherapy.
Falanga A
Haemostasis; 1998; 28 Suppl 3():50-60. PubMed ID: 10069762
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms and risk factors of thrombosis in cancer.
Falanga A; Russo L; Milesi V; Vignoli A
Crit Rev Oncol Hematol; 2017 Oct; 118():79-83. PubMed ID: 28917273
[TBL] [Abstract][Full Text] [Related]
10. Clotting mechanisms and cancer: implications in thrombus formation and tumor progression.
Falanga A; Marchetti M; Vignoli A; Balducci D
Clin Adv Hematol Oncol; 2003 Nov; 1(11):673-8. PubMed ID: 16258469
[TBL] [Abstract][Full Text] [Related]
11. The thrombophilic state in cancer patients.
Gouin-Thibault I; Achkar A; Samama MM
Acta Haematol; 2001; 106(1-2):33-42. PubMed ID: 11549775
[TBL] [Abstract][Full Text] [Related]
12. Overview of the postulated mechanisms linking cancer and thrombosis.
ten Cate H; Falanga A
Pathophysiol Haemost Thromb; 2008; 36(3-4):122-30. PubMed ID: 19176985
[TBL] [Abstract][Full Text] [Related]
13. The thrombophilic state induced by therapeutic agents in the cancer patient.
Lee AY; Levine MN
Semin Thromb Hemost; 1999; 25(2):137-45. PubMed ID: 10357081
[TBL] [Abstract][Full Text] [Related]
14. Cancer-associated thrombosis.
Zwicker JI; Furie BC; Furie B
Crit Rev Oncol Hematol; 2007 May; 62(2):126-36. PubMed ID: 17293122
[TBL] [Abstract][Full Text] [Related]
15. Procoagulant mechanisms in tumour cells.
Falanga A; Panova-Noeva M; Russo L
Best Pract Res Clin Haematol; 2009 Mar; 22(1):49-60. PubMed ID: 19285272
[TBL] [Abstract][Full Text] [Related]
16. Cancer related thrombophilia: clinical importance and management strategies.
Gupta PK; Charan VD; Kumar H
J Assoc Physicians India; 2005 Oct; 53():877-82. PubMed ID: 16459532
[TBL] [Abstract][Full Text] [Related]
17. Blood levels of nitric oxide, C-reactive protein, and tumor necrosis factor-alpha are upregulated in patients with malignancy-associated hypercoagulable state: pathophysiologic implications.
Fareed D; Iqbal O; Tobu M; Hoppensteadt DA; Fareed J
Clin Appl Thromb Hemost; 2004 Oct; 10(4):357-64. PubMed ID: 15497022
[TBL] [Abstract][Full Text] [Related]
18. Role of current and emerging antithrombotics in thrombosis and cancer.
Mousa SA
Drugs Today (Barc); 2006 May; 42(5):331-50. PubMed ID: 16801996
[TBL] [Abstract][Full Text] [Related]
19. The blood coagulation mechanism in multiple myeloma.
Zangari M; Saghafifar F; Mehta P; Barlogie B; Fink L; Tricot G
Semin Thromb Hemost; 2003 Jun; 29(3):275-82. PubMed ID: 12888931
[TBL] [Abstract][Full Text] [Related]
20. Molecular basis for the relationship between thrombosis and cancer.
Rickles FR; Falanga A
Thromb Res; 2001 Jun; 102(6):V215-24. PubMed ID: 11516455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
